Skip to main content

Table 2 Factors associated with an ultralow HIV-1 DNA level (<20 copies/106 PBMCs) at week 96

From: A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study

Variables   Univariate    Multivariate  
  OR 95% CI P OR 95% CI P
Sex    0.100    0.092
 Male 1.00    1.00   
 Female 2.42 (0.85–6.93)   3.40 (0.82–14.15)  
Age (years) 1.01 (0.96–1.07) 0.633    
Time from diagnosis to ART (months) 0.98 (0.94–1.01) 0.183    
Transmission route    0.857    
 Homosexual 1.00      
 Heterosexual 1.36 (0.44–4.27)     
 Others 1.42 (0.20–9.82)     
HIV-1 subtype    0.717    
 AE 1.00      
 B/C/BC 1.48 (0.37–5.96) 0.584    
 Others 1.68 (0.48–5.95) 0.418    
ART therapy    0.477    
 AZT/d4T + 3TC + NVP 1.00      
 TDF + 3TC + EFV 0.67 (0.22–2.04)     
Plasma viral load at enrollment (log copies/mL) 0.71 (0.36–1.41) 0.330    
HIV-1 DNA at enrollment (log copies/106 PBMCs) 0.72 (0.17–3.11) 0.656    
CD4+ T-cell count at enrollment (cells/μL) 1.00 (1.00–1.01) 0.134    
Nadir CD4+ T-cell count (cells/μL) 1.00 (1.00–1.01) 0.129    
CD8+ T-cell count at enrollment (cells/μL) 1.00 (1.00–1.00) 0.528    
CD4/CD8 ratio at enrollment 1.19 (0.95–1.48) 0.124    
Plasma viral load at week 96    0.808    
 Undetectable 1.00      
 Viremia 0.75 (0.07–7.66)     
CD4+ T-cell count at week 96 (cells/μL) 1.00 (1.00–1.00) 0.709    
CD8+ T-cell count at week 96 (cells/μL) 0.99 (0.99–0.99)a 0.018 1.00 (0.99–1.00) 0.462
CD4/CD8 ratio at week 96 (per 0.1 increase) 1.28 (1.05–1.55) 0.014 1.29 (1.05–1.59) 0.017
  1. OR Odds ratio, CI confidence interval, ART Antiretroviral therapy, PBMCs Peripheral blood mononuclear cells
  2. a, 0.993~0.999